Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1999;99:1733-1739

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moghadasian, M. H.
Right arrow Articles by Frohlich, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moghadasian, M. H.
Right arrow Articles by Frohlich, J. J.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Related Collections
Right arrow Animal models of human disease
Right arrow Lipid and lipoprotein metabolism

(Circulation. 1999;99:1733-1739.)
© 1999 American Heart Association, Inc.


Basic Science Reports

Proatherogenic and Antiatherogenic Effects of Probucol and Phytosterols in Apolipoprotein E–Deficient Mice

Possible Mechanisms of Action

Mohammed H. Moghadasian, DVM, MSc, PhD; Bruce M. McManus, MD, PhD, FRCPC; David V. Godin, PhD; Brian Rodrigues, PhD; Jiri J. Frohlich, MD, FRCPC

From the Atherosclerosis Specialty Laboratory (M.H.M., J.J.F.) and Cardiovascular Research Laboratory (B.M.M.), Department of Pathology and Laboratory Medicine, Department of Pharmacology and Therapeutics (D.V.G.), Faculty of Pharmaceutical Sciences (B.R.), University of British Columbia and St. Paul's Hospital, Vancouver, Canada.

Correspondence to Jiri J. Frohlich, MD, #180-1081 Burrard St, Vancouver, BC, Canada V6Z 1Y6. E-mail jifr{at}unixg.ubc.ca

Background—The effects of probucol and a phytosterol mixture (FCP-3PI) on atherosclerotic lesion formation, plasma lipoproteins, hepatic and lipoprotein lipase activities, antioxidant enzyme activities, and plasma fibrinogen were investigated in apolipoprotein E–knockout (apoE-KO) mice.

Methods and Results—Three groups of 8 mice were fed a diet containing 9% (wt/wt) fat (controls) or the foregoing diet supplemented with either 1% (wt/wt) probucol (the probucol group) or 2% (wt/wt) FCP-3PI (the FCP-3PI group) for 20 weeks. Compared with controls, atherosclerotic lesion size was 3 times greater in the probucol group, whereas it was decreased by half in the FCP-3PI group. Probucol treatment resulted in high plasma probucol concentrations, which correlated (r=0.69) with the lesion area. HDL cholesterol was reduced (>75%) in the probucol group and slightly increased (14%) in the FCP-3PI–treated group. Postheparin lipoprotein lipase (LPL) activity was significantly reduced in both treatment groups, but only FCP-3PI significantly decreased hepatic lipase activity. Plasma fibrinogen was increased 42% by probucol and decreased 19% by FCP-3PI relative to controls. Probucol significantly increased plasma glutathione reductase, glutathione peroxidase, and superoxide dismutase activities (P<0.05). In contrast to findings in apoE-KO mice, there was no probucol-induced atherosclerosis in their wild-type counterparts fed the same dose for the same period of time.

Conclusions—Antiatherogenic activity of FCP-3PI in apoE-KO mice is associated with an increase in HDL cholesterol concentration along with decreases in hepatic lipase activity and plasma fibrinogen concentrations. Proatherogenic effects of probucol may be related to increased plasma fibrinogen, decreased HDL cholesterol concentrations along with decreased LPL activity, or its direct "toxicity" due to very high plasma concentration. Our studies demonstrate that the antioxidant and cholesterol-lowering properties of probucol do not prevent atherogenesis in this particular animal model.


Key Words: hypercholesterolemia • atherosclerosis • lipoproteins • fibrinogen • antioxidants




This article has been cited by other articles:


Home page
J. Lipid Res.Home page
G. Silbernagel, G. Fauler, W. Renner, E. M. Landl, M. M. Hoffmann, B. R. Winkelmann, B. O. Boehm, and W. Marz
The relationships of cholesterol metabolism and plasma plant sterols with the severity of coronary artery disease
J. Lipid Res., February 1, 2009; 50(2): 334 - 341.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
S. Helske, T. Miettinen, H. Gylling, M. Mayranpaa, J. Lommi, H. Turto, K. Werkkala, M. Kupari, and P. T. Kovanen
Accumulation of cholesterol precursors and plant sterols in human stenotic aortic valves
J. Lipid Res., July 1, 2008; 49(7): 1511 - 1518.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
O. Weingartner, D. Lutjohann, S. Ji, N. Weisshoff, F. List, T. Sudhop, K. von Bergmann, K. Gertz, J. Konig, H.-J. Schafers, et al.
Vascular effects of diet supplementation with plant sterols.
J. Am. Coll. Cardiol., April 22, 2008; 51(16): 1553 - 1561.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
R. A. Othman, M. Suh, G. Fischer, N. Azordegan, N. Riediger, K. Le, D. S. Jassal, and M. H. Moghadasian
A comparison of the effects of fish oil and flaxseed oil on cardiac allograft chronic rejection in rats
Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1452 - H1458.
[Abstract] [Full Text] [PDF]


Home page
Plant Physiol.Home page
Q. Chen, L. Steinhauer, J. Hammerlindl, W. Keller, and J. Zou
Biosynthesis of Phytosterol Esters: Identification of a Sterol O-Acyltransferase in Arabidopsis
Plant Physiology, November 1, 2007; 145(3): 974 - 984.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
B. J. Wu, N. Di Girolamo, K. Beck, C. G. Hanratty, K. Choy, J. Y. Hou, M. R. Ward, and R. Stocker
Probucol [4,4'-[(1-Methylethylidene)bis(thio)]bis-[2,6-bis(1,1-dimethylethyl)phenol]] Inhibits Compensatory Remodeling and Promotes Lumen Loss Associated with Atherosclerosis in Apolipoprotein E-Deficient Mice
J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 477 - 484.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
B. Nashed, B. Yeganeh, K. T. HayGlass, and M. H. Moghadasian
Antiatherogenic Effects of Dietary Plant Sterols Are Associated with Inhibition of Proinflammatory Cytokine Production in Apo E-KO Mice
J. Nutr., October 1, 2005; 135(10): 2438 - 2444.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
K. R. Wilund, L. Yu, F. Xu, G. L. Vega, S. M. Grundy, J. C. Cohen, and H. H. Hobbs
No Association Between Plasma Levels of Plant Sterols and Atherosclerosis in Mice and Men
Arterioscler Thromb Vasc Biol, December 1, 2004; 24(12): 2326 - 2332.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
R. Stocker and J. F. Keaney Jr.
Role of Oxidative Modifications in Atherosclerosis
Physiol Rev, October 1, 2004; 84(4): 1381 - 1478.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
P. M. Clifton, M. Noakes, D. Ross, A. Fassoulakis, M. Cehun, and P. Nestel
High dietary intake of phytosterol esters decreases carotenoids and increases plasma plant sterol levels with no additional cholesterol lowering
J. Lipid Res., August 1, 2004; 45(8): 1493 - 1499.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
E. Waddington, I. B Puddey, and K. D Croft
Red wine polyphenolic compounds inhibit atherosclerosis in apolipoprotein E-deficient mice independently of effects on lipid peroxidation
Am. J. Clinical Nutrition, January 1, 2004; 79(1): 54 - 61.
[Abstract] [Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
M. B. Katan, S. M. Grundy, P. Jones, M. Law, T. Miettinen, R. Paoletti, and Stresa Workshop Participants
Efficacy and Safety of Plant Stanols and Sterols in the Management of Blood Cholesterol Levels
Mayo Clin. Proc., August 1, 2003; 78(8): 965 - 978.
[Abstract] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
L. Li, E. W. Lee, H. Ji, and Z. Zukowska
Neuropeptide Y-Induced Acceleration of Postangioplasty Occlusion of Rat Carotid Artery
Arterioscler Thromb Vasc Biol, July 1, 2003; 23(7): 1204 - 1210.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
C. L. Sundell, P. K. Somers, C. Q. Meng, L. K. Hoong, K.-L. Suen, R. R. Hill, L. K. Landers, A. Chapman, D. Butteiger, M. Jones, et al.
AGI-1067: A Multifunctional Phenolic Antioxidant, Lipid Modulator, Anti-Inflammatory and Antiatherosclerotic Agent
J. Pharmacol. Exp. Ther., June 1, 2003; 305(3): 1116 - 1123.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Gervais, S. Pons, A. Nicoletti, C. Cosson, J.-F. Giudicelli, and C. Richer
Fluvastatin Prevents Renal Dysfunction and Vascular NO Deficit in Apolipoprotein E-Deficient Mice
Arterioscler Thromb Vasc Biol, February 1, 2003; 23(2): 183 - 189.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. F. Bentzon, G. Pasterkamp, and E. Falk
Expansive Remodeling Is a Response of the Plaque-Related Vessel Wall in Aortic Roots of ApoE-Deficient Mice: An Experiment of Nature
Arterioscler Thromb Vasc Biol, February 1, 2003; 23(2): 257 - 262.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
F. Violi, F. Micheletta, and L. Iuliano
Antioxidants and atherosclerosis
Eur. Heart J. Suppl., March 1, 2002; 4(suppl_B): B17 - B21.
[Abstract] [PDF]


Home page
FASEB J.Home page
M. H. MOGHADASIAN, B. M. McMANUS, L. B. NGUYEN, S. SHEFER, M. NADJI, D. V. GODIN, T. J. GREEN, J. HILL, Y. YANG, C. H. SCUDAMORE, et al.
Pathophysiology of apolipoprotein E deficiency in mice: relevance to apo E-related disorders in humans
FASEB J, December 1, 2001; 15(14): 2623 - 2630.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
P. K. Witting, K. Pettersson, J. Letters, and R. Stocker
Site-Specific Antiatherogenic Effect of Probucol in Apolipoprotein E-Deficient Mice
Arterioscler Thromb Vasc Biol, August 1, 2000; 20 (8): e26 - e33.
[Abstract] [Full Text] [PDF]